Different causes of reduced sensitivity to thyroid hormone: Diagnosis and clinical management

Clinical Endocrinology

Volumn 79, Issue 5, 2013, Pages 595-605

  Visser, W Edward ^a   Van Mullem, Alies A A ^a   Visser, Theo J ^a   Peeters, Robin P ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

3,3',5 TRIIODOTHYROACETIC ACID SULFATE; ANTICONVULSIVE AGENT; ANTIOXIDANT; ATENOLOL; BINDING PROTEIN; CARRIER PROTEIN; CELL NUCLEUS RECEPTOR; DIIODOTHYROPROPIONIC ACID; GLUTATHIONE PEROXIDASE 3; GROWTH HORMONE; LIOTHYRONINE; PROPIONIC ACID DERIVATIVE; PROPYLTHIOURACIL; PROTIRELIN; SECIS BINDING PROTEIN 2; SELENIUM; SELENOCYSTEINE; SELENOPROTEIN P; THIAMAZOLE; THYROID HORMONE RECEPTOR ALPHA; THYROID HORMONE RECEPTOR BETA; THYROXINE; THYROXINE DEIODINASE; UNCLASSIFIED DRUG;

3' UNTRANSLATED REGION; ALLAN HERNDON DUDLEY SYNDROME; BONE AGE; BRAIN DEVELOPMENT; CATCH UP GROWTH; COGNITIVE DEFECT; DEIODINATION; DIAGNOSTIC TEST; DIFFERENTIAL DIAGNOSIS; DRUG EFFICACY; FRAMESHIFT MUTATION; GENE; GENE INSERTION SEQUENCE; GENE MUTATION; GROUPS BY AGE; GROWTH RETARDATION; HORMONE SENSITIVITY; HORMONE TRANSPORT; HUMAN; HYPERTHYROIDISM; HYPOTHALAMUS HYPOPHYSIS THYROID SYSTEM; HYPOTHYROIDISM; LABORATORY TEST; MCT8 GENE; NONHUMAN; NUTRITIONAL SUPPORT; PHENOTYPE; PHENOTYPIC VARIATION; PRIORITY JOURNAL; PSYCHOMOTOR RETARDATION; REVIEW; SEIZURE; TACHYCARDIA; THYROID DISEASE; THYROID FUNCTION TEST; THYROID HORMONE METABOLISM; THYROID HORMONE RESISTANCE; TREMOR; X LINKED MENTAL RETARDATION;

CELL MEMBRANE; HUMANS; MONOCARBOXYLIC ACID TRANSPORTERS; RNA-BINDING PROTEINS; THYROID GLAND; THYROID HORMONES;

EID: 84885328980     PISSN: 03000664     EISSN: 13652265     Source Type: Journal    
DOI: 10.1111/cen.12281     Document Type: Review

References (81)

1. Refetoff, S., DeWind, L.T., &, DeGroot, L.J., (1967) Familial syndrome combining deaf-mutism, stuppled epiphyses, goiter and abnormally high PBI: possible target organ refractoriness to thyroid hormone. Journal of Clinical Endocrinology and Metabolism, 27, 279-294.
2. Refetoff, S., DeGroot, L.J., Benard, B., et al,. (1972) Studies of a sibship with apparent hereditary resistance to the intracellular action of thyroid hormone. Metabolism, 21, 723-756.
3. Weinberger, C., Thompson, C.C., Ong, E.S., et al,. (1986) The c-erb-A gene encodes a thyroid hormone receptor. Nature, 324, 641-646.
4. Thompson, C.C., Weinberger, C., Lebo, R., et al,. (1987) Identification of a novel thyroid hormone receptor expressed in the mammalian central nervous system. Science, 237, 1610-1614.
5. Sakurai, A., Takeda, K., Ain, K., et al,. (1989) Generalized resistance to thyroid hormone associated with a mutation in the ligand-binding domain of the human thyroid hormone receptor beta. Proceedings of the National Academy of Sciences of the United States of America, 86, 8977-8981.
6. Dumitrescu, A.M., &, Refetoff, S., (2013) The syndromes of reduced sensitivity to thyroid hormone. Biochimica et Biophysica Acta, 1830, 3987-4003.
7. Ferrara, A.M., Onigata, K., Ercan, O., et al,. (2012) Homozygous thyroid hormone receptor beta-gene mutations in resistance to thyroid hormone: three new cases and review of the literature. Journal of Clinical Endocrinology and Metabolism, 97, 1328-1336.
8. Dumitrescu, A.M., Liao, X.H., Best, T.B., et al,. (2004) A novel syndrome combining thyroid and neurological abnormalities is associated with mutations in a monocarboxylate transporter gene. American Journal of Human Genetics, 74, 168-175.
9. Friesema, E.C., Grueters, A., Biebermann, H., et al,. (2004) Association between mutations in a thyroid hormone transporter and severe X-linked psychomotor retardation. Lancet, 364, 1435-1437.
10. Dumitrescu, A.M., Liao, X.H., Abdullah, M.S., et al,. (2005) Mutations in SECISBP2 result in abnormal thyroid hormone metabolism. Nature Genetics, 37, 1247-1252.
11. Bochukova, E., Schoenmakers, N., Agostini, M., et al,. (2012) A mutation in the thyroid hormone receptor alpha gene. New England Journal of Medicine, 366, 243-249.
12. van Mullem, A., van Heerebeek, R., Chrysis, D., et al,. (2012) Clinical phenotype and mutant TRalpha1. New England Journal of Medicine, 366, 1451-1453.
13. Cheng, S.Y., Leonard, J.L., &, Davis, P.J., (2010) Molecular aspects of thyroid hormone actions. Endocrine Reviews, 31, 139-170.
14. Nunez, J., Celi, F.S., Ng, L., et al,. (2008) Multigenic control of thyroid hormone functions in the nervous system. Molecular and Cellular Endocrinology, 287, 1-12.
15. Bianco, A.C., Salvatore, D., Gereben, B., et al,. (2002) Biochemistry, cellular and molecular biology, and physiological roles of the iodothyronine selenodeiodinases. Endocrine Reviews, 23, 38-89.
16. Gereben, B., Zavacki, A.M., Ribich, S., et al,. (2008) Cellular and molecular basis of deiodinase-regulated thyroid hormone signaling. Endocrine Reviews, 29, 898-938.
17. Peeters, R.P., Wouters, P.J., Kaptein, E., et al,. (2003) Reduced activation and increased inactivation of thyroid hormone in tissues of critically ill patients. Journal of Clinical Endocrinology and Metabolism, 88, 3202-3211.
18. Arrojo, E.D.R., Fonseca, T.L., Werneck-de-Castro, J.P., et al,. (2013) Role of the type 2 iodothyronine deiodinase (D2) in the control of thyroid hormone signaling. Biochimica et Biophysica Acta, 1830, 3956-3964.
19. Peeters, R.P., Hernandez, A., Ng, L., et al,. (2013) Cerebellar abnormalities in mice lacking type 3 deiodinase and partial reversal of phenotype by deletion of thyroid hormone receptor alpha1. Endocrinology, 154, 550-561.
20. Visser, W.E., Friesema, E.C., Jansen, J., et al,. (2008) Thyroid hormone transport in and out of cells. Trends in Endocrinology and Metabolism, 19, 50-56.
21. Friesema, E.C., Ganguly, S., &, Abdalla, A., (2003) Manning Fox JE, Halestrap AP, Visser TJ. Identification of monocarboxylate transporter 8 as a specific thyroid hormone transporter. Journal of Biological Chemistry, 278, 40128-40135.
22. Friesema, E.C., Kuiper, G.G., Jansen, J., et al,. (2006) Thyroid hormone transport by the human monocarboxylate transporter 8 and its rate-limiting role in intracellular metabolism. Molecular Endocrinology, 20, 2761-2772.
23. Friesema, E.C., Jansen, J., Jachtenberg, J.W., et al,. (2008) Effective cellular uptake and efflux of thyroid hormone by human monocarboxylate transporter 10. Molecular Endocrinology, 22, 1357-1369.
24. Kim, D.K., Kanai, Y., Chairoungdua, A., et al,. (2001) Expression cloning of a Na+-independent aromatic amino acid transporter with structural similarity to H+/monocarboxylate transporters. Journal of Biological Chemistry, 276, 17221-17228.
25. Pizzagalli, F., Hagenbuch, B., Stieger, B., et al,. (2002) Identification of a novel human organic anion transporting polypeptide as a high affinity thyroxine transporter. Molecular Endocrinology, 16, 2283-2296.
26. Visser, W.E., Friesema, E.C., &, Visser, T.J., (2011) Minireview: thyroid hormone transporters: the knowns and the unknowns. Molecular Endocrinology, 25, 1-14.
27. Schwartz, C.E., May, M.M., Carpenter, N.J., et al,. (2005) Allan-Herndon-Dudley syndrome and the monocarboxylate transporter 8 (MCT8) gene. American Journal of Human Genetics, 77, 41-53.
28. Visser, W.E., Jansen, J., Friesema, E.C., et al,. (2009) Novel pathogenic mechanism suggested by ex vivo analysis of MCT8 (SLC16A2) mutations. Human Mutation, 30, 29-38.
29. Friesema, E.C., Jansen, J., Heuer, H., et al,. (2006) Mechanisms of disease: psychomotor retardation and high T3 levels caused by mutations in monocarboxylate transporter 8. Nature Clinical Practice Endocrinology & Metabolism, 2, 512-523.
30. Jansen, J., Friesema, E.C., Kester, M.H., et al,. (2007) Functional analysis of monocarboxylate transporter 8 mutations identified in patients with X-linked psychomotor retardation and elevated serum triiodothyronine. Journal of Clinical Endocrinology and Metabolism, 92, 2378-2381.
31. Trajkovic-Arsic, M., Visser, T.J., Darras, V.M., et al,. (2010) Consequences of monocarboxylate transporter 8 deficiency for renal transport and metabolism of thyroid hormones in mice. Endocrinology, 151, 802-809.
32. Di Cosmo, C., Liao, X.H., Dumitrescu, A.M., et al,. (2010) Mice deficient in MCT8 reveal a mechanism regulating thyroid hormone secretion. The Journal of Clinical Investigation, 120, 3377-3388.
33. Trajkovic-Arsic, M., Muller, J., Darras, V.M., et al,. (2010) Impact of monocarboxylate transporter-8 deficiency on the hypothalamus-pituitary-thyroid axis in mice. Endocrinology, 151, 5053-5062.
34. Liao, X.H., Di Cosmo, C., Dumitrescu, A.M., et al,. (2011) Distinct roles of deiodinases on the phenotype of Mct8 defect: a comparison of eight different mouse genotypes. Endocrinology, 152, 1180-1191.
35. Visser, W.E., de Rijke, Y.B., van Toor, H., et al,. (2011) Thyroid status in a large cohort of patients with mental retardation: the TOP-R (Thyroid Origin of Psychomotor Retardation) study. Clinical Endocrinology, 75, 395-401.
36. Oppenheimer, J.H., &, Schwartz, H.L., (1997) Molecular basis of thyroid hormone-dependent brain development. Endocrine Reviews, 18, 462-475.
37. Mayerl, S., Visser, T.J., Bauer, R., et al,. (2012) Consequences of brain-specific thyroid hormone deprivation in mct8/oatp1c1 double knockout mice. Thyroid, 22 (S1), A-2.
38. Roberts, L.M., Woodford, K., Zhou, M., et al,. (2008) Expression of the thyroid hormone transporters monocarboxylate transporter-8 (SLC16A2) and organic ion transporter-14 (SLCO1C1) at the blood-brain barrier. Endocrinology, 149, 6251-6261.
39. Biebermann, H., Ambrugger, P., Tarnow, P., et al,. (2005) Extended clinical phenotype, endocrine investigations and functional studies of a loss-of-function mutation A150V in the thyroid hormone specific transporter MCT8. European Journal of Endocrinology, 153, 359-366.
40. Namba, N., Etani, Y., Kitaoka, T., et al,. (2008) Clinical phenotype and endocrinological investigations in a patient with a mutation in the MCT8 thyroid hormone transporter. European Journal of Pediatrics, 167, 785-791.
41. Wemeau, J.L., Pigeyre, M., Proust-Lemoine, E., et al,. (2008) Beneficial effects of propylthiouracil plus L-thyroxine treatment in a patient with a mutation in MCT8. Journal of Clinical Endocrinology and Metabolism, 93, 2084-2088.
42. Horn, S., Kersseboom, S., Mayerl, S., et al,. (2013) Tetrac Can Replace Thyroid Hormone During Brain Development in Mouse Mutants Deficient in the Thyroid Hormone Transporter Mct8. Endocrinology, 154, 968-979.
43. Di Cosmo, C., Liao, X.H., Dumitrescu, A.M., et al,. (2009) A thyroid hormone analog with reduced dependence on the monocarboxylate transporter 8 for tissue transport. Endocrinology, 150, 4450-4458.
44. Verge, C.F., Konrad, D., Cohen, M., et al,. (2012) Diiodothyropropionic Acid (DITPA) in the Treatment of MCT8 Deficiency. Journal of Clinical Endocrinology and Metabolism, 97, 4515-4523.
45. Schoenmakers, E., Agostini, M., Mitchell, C., et al,. (2010) Mutations in the selenocysteine insertion sequence-binding protein 2 gene lead to a multisystem selenoprotein deficiency disorder in humans. The Journal of Clinical Investigation, 120, 4220-4235.
46. Di Cosmo, C., McLellan, N., Liao, X.H., et al,. (2009) Clinical and molecular characterization of a novel selenocysteine insertion sequence-binding protein 2 (SBP2) gene mutation (R128X). Journal of Clinical Endocrinology and Metabolism, 94, 4003-4009.
47. Schomburg, L., Dumitrescu, A.M., Liao, X.H., et al,. (2009) Selenium supplementation fails to correct the selenoprotein synthesis defect in subjects with SBP2 gene mutations. Thyroid, 19, 277-281.
48. Hayashi, Y., Weiss, R.E., Sarne, D.H., et al,. (1995) Do clinical manifestations of resistance to thyroid hormone correlate with the functional alteration of the corresponding mutant thyroid hormone-beta receptors? Journal of Clinical Endocrinology and Metabolism, 80, 3246-3256.
49. Takeda, K., Sakurai, A., DeGroot, L.J., et al,. (1992) Recessive inheritance of thyroid hormone resistance caused by complete deletion of the protein-coding region of the thyroid hormone receptor-beta gene. Journal of Clinical Endocrinology and Metabolism, 74, 49-55.
50. Refetoff, S., &, Dumitrescu, A.M., (2007) Syndromes of reduced sensitivity to thyroid hormone: genetic defects in hormone receptors, cell transporters and deiodination. Best Practice and Research. Clinical Endocrinology and Metabolism, 21, 277-305.
51. Beck-Peccoz, P., Persani, L., Calebiro, D., et al,. (2006) Syndromes of hormone resistance in the hypothalamic-pituitary-thyroid axis. Best Practice and Research. Clinical Endocrinology and Metabolism, 20, 529-546.
52. Mitchell, C.S., Savage, D.B., Dufour, S., et al,. (2010) Resistance to thyroid hormone is associated with raised energy expenditure, muscle mitochondrial uncoupling, and hyperphagia. The Journal of Clinical Investigation, 120, 1345-1354.
53. Bassett, J.H., &, Williams, G.R., (2009) The skeletal phenotypes of TRalpha and TRbeta mutant mice. Journal of Molecular Endocrinology, 42, 269-282.
54. Persani, L., Borgato, S., Romoli, R., et al,. (1998) Changes in the degree of sialylation of carbohydrate chains modify the biological properties of circulating thyrotropin isoforms in various physiological and pathological states. Journal of Clinical Endocrinology and Metabolism, 83, 2486-2492.
55. Ercan-Fang, S., Schwartz, H.L., Mariash, C.N., et al,. (2000) Quantitative assessment of pituitary resistance to thyroid hormone from plots of the logarithm of thyrotropin versus serum free thyroxine index. Journal of Clinical Endocrinology and Metabolism, 85, 2299-2303.
56. Bertenshaw, R., Sarne, D., Tornari, J., et al,. (1992) Sequencing of the variant thyroxine-binding globulin (TBG)-San Diego reveals two nucleotide substitutions. Biochimica et Biophysica Acta, 1139, 307-310.
57. Cartwright, D., O'Shea, P., Rajanayagam, O., et al,. (2009) Familial dysalbuminemic hyperthyroxinemia: a persistent diagnostic challenge. Clinical Chemistry, 55, 1044-1046.
58. Beck-Peccoz, P., Brucker-Davis, F., Persani, L., et al,. (1996) Thyrotropin-secreting pituitary tumors. Endocrine Reviews, 17, 610-638.
59. Weiss, R.E., Hayashi, Y., Nagaya, T., et al,. (1996) Dominant inheritance of resistance to thyroid hormone not linked to defects in the thyroid hormone receptor alpha or beta genes may be due to a defective cofactor. Journal of Clinical Endocrinology and Metabolism, 81, 4196-4203.
60. Reutrakul, S., Sadow, P.M., Pannain, S., et al,. (2000) Search for abnormalities of nuclear corepressors, coactivators, and a coregulator in families with resistance to thyroid hormone without mutations in thyroid hormone receptor beta or alpha genes. Journal of Clinical Endocrinology and Metabolism, 85, 3609-3617.
61. Collingwood, T.N., Wagner, R., Matthews, C.H., et al,. (1998) A role for helix 3 of the TRbeta ligand-binding domain in coactivator recruitment identified by characterization of a third cluster of mutations in resistance to thyroid hormone. EMBO Journal, 17, 4760-4770.
62. Yoh, S.M., Chatterjee, V.K., &, Privalsky, M.L., (1997) Thyroid hormone resistance syndrome manifests as an aberrant interaction between mutant T3 receptors and transcriptional corepressors. Molecular Endocrinology, 11, 470-480.
63. Weiss, R.E., Marcocci, C., Bruno-Bossio, G., et al,. (1993) Multiple genetic factors in the heterogeneity of thyroid hormone resistance. Journal of Clinical Endocrinology and Metabolism, 76, 257-259.
64. Weiss, R.E., Weinberg, M., &, Refetoff, S., (1993) Identical mutations in unrelated families with generalized resistance to thyroid hormone occur in cytosine-guanine-rich areas of the thyroid hormone receptor beta gene. Analysis of 15 families. The Journal of Clinical Investigation, 91, 2408-2415.
65. Suzuki, H., Willingham, M.C., &, Cheng, S.Y., (2002) Mice with a mutation in the thyroid hormone receptor beta gene spontaneously develop thyroid carcinoma: a mouse model of thyroid carcinogenesis. Thyroid, 12, 963-969.
66. Radetti, G., Persani, L., Molinaro, G., et al,. (1997) Clinical and hormonal outcome after two years of triiodothyroacetic acid treatment in a child with thyroid hormone resistance. Thyroid, 7, 775-778.
67. Anselmo, J., Cao, D., Karrison, T., et al,. (2004) Fetal loss associated with excess thyroid hormone exposure. JAMA, 292, 691-695.
68. Weiss, R.E., Dumitrescu, A., &, Refetoff, S., (2010) Approach to the patient with resistance to thyroid hormone and pregnancy. Journal of Clinical Endocrinology and Metabolism, 95, 3094-3102.
69. Gothe, S., Wang, Z., Ng, L., et al,. (1999) Mice devoid of all known thyroid hormone receptors are viable but exhibit disorders of the pituitary-thyroid axis, growth, and bone maturation. Genes & Development, 13, 1329-1341.
70. Morte, B., Manzano, J., Scanlan, T., et al,. (2002) Deletion of the thyroid hormone receptor alpha 1 prevents the structural alterations of the cerebellum induced by hypothyroidism. Proceedings of the National Academy of Sciences of the United States of America, 99, 3985-3989.
71. Kaneshige, M., Suzuki, H., Kaneshige, K., et al,. (2001) A targeted dominant negative mutation of the thyroid hormone alpha 1 receptor causes increased mortality, infertility, and dwarfism in mice. Proceedings of the National Academy of Sciences of the United States of America, 98, 15095-15100.
72. Liu, Y.Y., Tachiki, K.H., &, Brent, G.A., (2002) A targeted thyroid hormone receptor alpha gene dominant-negative mutation (P398H) selectively impairs gene expression in differentiated embryonic stem cells. Endocrinology, 143, 2664-2672.
73. Quignodon, L., Vincent, S., Winter, H., et al,. (2007) A point mutation in the activation function 2 domain of thyroid hormone receptor alpha1 expressed after CRE-mediated recombination partially recapitulates hypothyroidism. Molecular Endocrinology, 21, 2350-2360.
74. Tinnikov, A., Nordstrom, K., Thoren, P., et al,. (2002) Retardation of post-natal development caused by a negatively acting thyroid hormone receptor alpha1. EMBO Journal, 21, 5079-5087.
75. Vennstrom, B., Mittag, J., &, Wallis, K., (2008) Severe psychomotor and metabolic damages caused by a mutant thyroid hormone receptor alpha 1 in mice: can patients with a similar mutation be found and treated? Acta Paediatrica, 97, 1605-1610.
76. van Mullem, A.A., Chrysis, D., Eythimiadou, A., et al,. (2013) Clinical phenotype of a new type of thyroid hormone resistance caused by a mutation of the TRalpha1 receptor; consequences of LT4 treatment. Journal of Clinical Endocrinology and Metabolism, 98, 3029-3038.
77. Wagner, R.L., Apriletti, J.W., McGrath, M.E., et al,. (1995) A structural role for hormone in the thyroid hormone receptor. Nature, 378, 690-697.
78. Barca-Mayo, O., Liao, X.H., Alonso, M., et al,. (2011) Thyroid hormone receptor alpha and regulation of type 3 deiodinase. Molecular Endocrinology, 25, 575-583.
79. Macchia, P.E., Takeuchi, Y., Kawai, T., et al,. (2001) Increased sensitivity to thyroid hormone in mice with complete deficiency of thyroid hormone receptor alpha. Proceedings of the National Academy of Sciences of the United States of America, 98, 349-354.
80. Venero, C., Guadano-Ferraz, A., Herrero, A.I., et al,. (2005) Anxiety, memory impairment, and locomotor dysfunction caused by a mutant thyroid hormone receptor alpha1 can be ameliorated by T3 treatment. Genes & Development, 19, 2152-2163.
81. Wallis, K., Sjogren, M., van Hogerlinden, M., et al,. (2008) Locomotor deficiencies and aberrant development of subtype-specific GABAergic interneurons caused by an unliganded thyroid hormone receptor alpha1. Journal of Neuroscience, 28, 1904-1915.